FOLLOWUS
1.Henan University of Chinese Medicine, Zhengzhou (450046),China
2.The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou (450099), China
Prof. ZHU Ming-jun, E-mail: zhumingjun317@163.com
纸质出版日期:2022-09,
网络出版日期:2022-07-12,
录用日期:2022-01-25
Scan for full text
Hong-xin GUO, Jian-ru WANG, Guang-cao PENG, 等. 基于数据挖掘的中药治疗射血分数保留心衰用药规律研究[J]. Chinese Journal of Integrative Medicine, 2022,28(9):847-854.
Hong-xin GUO, Jian-ru WANG, Guang-cao PENG, et al. A Data Mining-Based Study on Medication Rules of Chinese Herbs to Treat Heart Failure with Preserved Ejection Fraction[J]. Chinese Journal of Integrative Medicine, 2022,28(9):847-854.
Hong-xin GUO, Jian-ru WANG, Guang-cao PENG, 等. 基于数据挖掘的中药治疗射血分数保留心衰用药规律研究[J]. Chinese Journal of Integrative Medicine, 2022,28(9):847-854. DOI: 10.1007/s11655-022-2892-5.
Hong-xin GUO, Jian-ru WANG, Guang-cao PENG, et al. A Data Mining-Based Study on Medication Rules of Chinese Herbs to Treat Heart Failure with Preserved Ejection Fraction[J]. Chinese Journal of Integrative Medicine, 2022,28(9):847-854. DOI: 10.1007/s11655-022-2892-5.
目的:
2
基于数据挖掘对中药治疗射血分数保留心衰 (HFPEF) 的用药规律进行总结
为临床用药提供参考.
方法:
2
检索中国知网 (CNKI)、万方数据 (Wanfang)、维普网 (VIP)、中国生物医学文献数据库 (CBM)、PubMed、Embase和Cochrane Library数据库中有关中药治疗HFPEF的文献
检索时限为各数据库建库起至2021年10月. 首先使用Microsoft Excel 2019建立数据库
然后使用R-Studio (Version 4.0.3)中apriori函数和hclust函数进行关联规则分析和层次聚类分析.
结果:
2
最终纳入合格文献182篇
共包含方剂92首
涉及单味中药130味
中药累计使用872次
平均每首处方含中药9.5味. 最常用的6味中药依次是黄芪、丹参、茯苓、甘草、桂枝和人参. 使用频次>5次的中药有35味
涉及11种功效类别
以补虚药、活血化瘀药和利水渗湿药占比最高
药性以温性和甘味为主
多归肺、心和脾经. 关联规则分析共得到黄芪&丹参、茯苓
桂枝&白术等26条较强关联. 层次聚类分析共得到4类中药组合
功效以益气温阳
活血利水为主.
结论:
2
HFPEF为本虚标实之证
核心病机为“虚”、“瘀”、“水”
以“虚”最为主要
与心肺脾三脏关系密切. 该病治以益气温阳、活血利水
黄芪配伍丹参为基础用药组合.
Objective:
2
To summarize the medication rules of Chinese herbs to treat heart failure with preserved ejection fraction (HFPEF) based on data mining and to provide references for clinical utilization.
Methods:
2
The China National Knowledge Infrastructure (CNKI)
Wanfang database (Wanfang)
VIP database (VIP)
Chinese Biomedical Literature (CBM)
PubMed
Embase
and Cochrane Library databases were searched from inception to October 2021 to identify relevant literature on treating HFPEF with Chinese herbs. Microsoft Excel 2019 was used to set up a database
and then
association rule analysis and hierarchical cluster analysis were performed by using apriori algorithm and hclust function respectively in R-Studio (Version 4.0.3).
Results:
2
A total of 182 qualified papers were included
involving a total of 92 prescriptions
130 Chinese herbs
and 872 individual herbs prescribed
with an average of 9.5 herbs per prescription. The six most frequently prescribed herbs were
Astragali Radix
(Huangqi)
Salviae Miltiorrhizae Radix Et Rhizoma
(Danshen)
Poria
(Fuling)
Glycyrrhizae Radix Et Rhizoma
(Gancao)
Cinnamomi Ramulus
(Guizhi)
and
Ginseng Radix Et Rhizoma
(Renshen). There were 35 herbs used more than 5 times
involving 11 efficacy categories. The top three categories were deficiency-tonifying herbs
blood-activating and stasis-removing herbs
and dampness-draining diuretic herbs. The most commonly used herbs were mainly warm and sweet. The primary meridian tropisms were Lung Meridian
Heart Meridian and Spleen Meridian. Association rule analysis yielded 26 association rules
such as
Astragali Radix
(Huangqi)
&
Salviae Miltiorrhizae Radix Et Rhizoma
(Danshen)
Poria
(Fuling)
Cinnamomi Ramulus
(Guizhi)
&
Atractylodis Macrocephalae Rhizoma
(Baizhu). Hierarchical cluster analysis yielded four herb classes
and their functions were mainly qi-replenishing and yang-warming
blood-activating and diuresis-inducing.
Conclusions:
2
HFPEF is the syndrome of root vacuity and tip repletion
and its core pathogenesis is "deficiency"
"stasis"
and "water"
with "deficiency" being the most principal
which is closely related to Xin (heart)
Fei (Lung)
and Pi (Spleen). The treatment of this disease occurs by improving qi
warming yang
activating blood and inducing diuresis.
Astragali Radix
(Huangqi) with
Salviae Miltiorrhizae Radix Et Rhizoma
(Danshen) is the basic combination of herbs applied.
heart failure with preserved ejection fractiondata miningChinese herbsmedication rulesassociation rulescluster analysis
heart failure with preserved ejection fractiondata miningChinese herbsmedication rulesassociation rulescluster analysis
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF,Coats AJS, et al. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association(HFA) of the ESC. Eur Heart J 2016;37:2129-2200.
Roger Véronique L. Epidemiology of heart failure: a contemporary perspective. Circ Res 2021;128:1421-1434.
Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol 2020;17:559-573.
Pfeffer MA, Shah AM, Borlaug BA. Heart failure with preserved ejection fraction in perspective. Circ Res 2019;124:1598-1617.
Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 2017;14:591-602.
Gladden JD, Linke WA, Redfield MM. Heart failure with preserved ejection fraction. Pflugers Arch 2014;466:1037-1053.
Campbell RT, Jhund PS, Castagno D, Hawkins NM, Petrie MC, McMurray JJ. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? J Am Coll Cardiol 2012;60:2349-2356.
Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ. Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur Heart J 2018;39:2780-2792.
Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study.J Am Coll Cardiol 2009;53:1119-1126.
Maurer MS, King DL, El-Khoury Rumbarger L, Packer M,Burkhoff D. Left heart failure with a normal ejection fraction: identification of different pathophysiologic mechanisms. J Card Fail 2005;11:177-187.
Kai H, Kuwahara F, Tokuda K, Imaizumi T. Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis. Hypertens Res 2005;28:483-490.
Zile MR, Baicu CF, Ikonomidis JS, Stroud RE, Nietert PJ,Bradshaw AD, et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation 2015;131:1247-1259.
Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383-1392.
Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP,Maggioni AP, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019;381:1609-1620.
Wang J, Yang R, Zhang F, Jia C, Wang P, Liu J, et al. The effect of Chinese herbal medicine on quality of life and exercise tolerance in heart failure with preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials. Front Physiol 2018;9:1420-1435.
Mei J, Xu H, Xu FQ, Ju JQ. Oral Chinese herbal medicine for heart failure with preserved ejection fraction: a meta-analysis. Chin J Integr Med 2019;25:770-777.
Yang LN, Wu ZL, Yang ZJ, Li SG, Ouyang CS. Exploring mechanism of key Chinese herbal medicine on breast cancer by data mining and network pharmacology methods.Chin J Integr Med 2021;27:919-926.
Liu JH, Huang YJ, Lv DY, Kuang WH, Zhang SJ. Research trend and application of data mining in the field of traditional Chinese medicine. China J Tradit Chin Med Pharm (Chin)2020;35:953-955.
Li Z, Hu YY, Zheng CY, Su QZ, An C, Luo XD, et al.Rules of meridians and acupoints selection in treatment of parkinson's disease based on data mining techniques. Chin J Integr Med 2020;26:624-628.
Tang SH, Shen D, Yang HJ. Analysis on composition rules of Chinese patent drugs treating pain-related diseases based on data mining method. Chin J Integr Med 2019;25:861-866.
Wang H, Liang YC. 2018 Guidelines for the diagnosis and treatment of heart failure in China. Chin J Cardiol (Chin)2018;46:760-789.
Chinese Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China (Volume I). Beijing: China Medical Science Press; 2020:45-52.
Gao XM, ed. Chinese materia medica. Beijing: China Press of Traditional Chinese Medicine; 2017:1-8.
Rousseeuw P, Hubert M, Struyf A. Clustering in an object-oriented environment. J Statis Software 1997;1:1-30.
Hao XX, Cui L, Wang YP, Li B, Wang XL, Xie SY, et al.Research progress of Astragali Radix in the treatment of heart failure. Chin J Integr Med Cardio-/Cerebrovascular Dis (Chin) 2018;16:1666-1668.
Li XH, Li HQ. Changes of Aquaporin-2 in water retention kidney disease and "wetness" in Chinese medicine. Chin J Integr Tradit West Nephrol (Chin) 2009;10:370-373.
Liu SJ, Gu Y, Jiang YR, Lin ST. The effects of astragalus on renal aquaporins of adriamycin induced nephrotic syndrome rats. Chin J Integr Tradit West Nephrol (Chin) 2004;5:627-630.
Jin YY, Zhai CL, Shen Z, Zhang MQ. Protective effect of sodium tanshinone liab against rat myocardial ischemia-reperfusion injury. Chin Archives Tradit Chin Med (Chin) 2014;32:1414-1416, 1548-1549.
Li JH, Qiao YJ, Hou LF, He XL. Researches on tanshinone of Salvia miltiorrhiza's fat-soluble active ingredient. J Hebei Univ (Natur Sci edition, Chin) 2015;35:217-224.
Zhao YH, Tang DD, Chen DQ, Feng YL, Li QF. Progress on chemical components and diuretic mechanisms of traditional Chinese diuretic medicines Poria cocos, Cortex Poriae, Polyporus umbellatus and Alisma orientalis. Chin J Pharmacol Toxicol (Chin) 2014;28:594-599.
Wang YZ, Zhang J, Zhao YL, Li T, Shen T, Li JQ, et al.Mycology, cultivation, traditional uses, phytochemistry and pharmacology of Wolfiporia cocos (Schwein.) Ryvarden et Gilb: a review. J Ethnopharmacol 2013;147:265-276.
Zheng Y, Yang XW. Poriacosones A and B: two new lanostane triterpenoids from Poria cocos. J Asian Nat Prod Res 2008;10:645-651.
Chen KJ, Wu ZG, Zhu MJ, Mao JY, Xu H. Expert consensus on diagnosis and treatment of chronic heart failure by integrated traditional Chinese and Western medicine. Chin J Integr Tradit West Med (Chin) 2016;36:133-141.
Cheng M, Liang XH, Zhao YY, Zhang XB, Chen SC.Compatibility of Radix astragali and Radix salviae miltiorrhiae for the treatment of cardio-cerebrovascular system diseases: research advances. J Int Pharm Res (Chin) 2017;44:500-503.
Wang M, Shan Y, Wu C, Cao P, Sun W, Han J, et al.Efficacy and safety of qishen yiqi dripping pill for heart failure with preserved ejection fraction: a systematic review and meta-analysis. Front Pharmacol 2021;11:626375.
Wang YP, Xiong J, Yan X, Li XH, Luo ZQ. Meta-analysis of supplemented Zhenwu Decoction for treating congestive heart-failure. China J Chin Mater Med (Chin)2016;41:3679-3685.
Tang Q, Wang Y, Li K. Zhenwu Decoction for chronic heart failure: Protocol for a systematic review and meta-analysis.Medicine (Baltimore) 2018;97:e11559.
Liu ZH, Yang Y, Yan WH. Meta-analysis of clinical efficacy of modified Wulingsan decoction in the treatment of chronic heart failure. Nei Mongol J Tradit Chin Med (Chin)2020;39:144-148.
0
浏览量
3
Downloads
1
CSCD
关联资源
相关文章
相关作者
相关机构